CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » NEWS

Oncology NEWS International. Vol. 11 No. 7
Pages: 1  2  
Next
 

MRI Finds Recurrences in Patients With Rising PSA Level

July 1, 2002

ATLANTA—Dynamic magnetic resonance imaging (MRI) may be able to detect recurrent prostate cancer after prostatectomy when the patient has a negative biopsy but a rising prostate-specific antigen (PSA) level.

This could potentially spare the patient the need for a second or third biopsy, said Miki Takeda, MD, a radiologist with Sapporo Medical University, Japan. She presented the findings at the 102nd Annual Meeting of the American Roentgen Ray Society (abstract 262).

According to Dr. Takeda, a rising PSA level following radical prostatectomy nearly always means recurrence of cancer. "In our hospital, about 30% of patients have rising PSA levels following radical prostatectomy," she said.

To test the ability of MRI to predict local recurrence, Dr. Takeda and her colleagues evaluated 21 patients with rising PSA levels who had undergone a radical prostatectomy. They examined the prostatic fossa with T2-weighted images. After a bolus injection of a gadolinium contrast agent, multisectional dynamic MR images were obtained every 10 to 15 second for 90 seconds (see Figure).

Although all patients had a negative ultrasound-guided biopsy, MRI suggested local recurrence in 17 of the 21 patients. "In most cases, a second or third biopsy would have been needed to confirm recurrence, and this takes time—time in which the patient’s PSA level may continue to rise," Dr. Takeda said.

Successful Treatment

Fifteen of the 17 patients with suggested local recurrence were treated with radiation therapy. PSA levels gradually declined in 10 of these patients after a 1-year follow-up period, and 7 were subsequently considered cancer free.

Pages: 1  2  
Next
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
FROM PHYSICIANS PRACTICE
Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND,  May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri,  May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?
Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC,  May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.
Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson,  May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.
Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker,  May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Skin Lesions
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Colorectal Lesions
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • New AUA Guidelines for Prostate Cancer Screening
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Genomics Studies Identify Testicular Cancer Risk Variants
  • Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
  • FDA Approves Erlotinib (Tarceva) as First-Line Lung Cancer Therapy for Certain Patients
Click here to subscribe to our newsletter


CancerNetwork on Facebook


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy